Q: Does the recent flurry of acquisitions of private biotech companies by pharma companies represent a new and continuing trend?
A: Yes—the recent acquisitions of Angiosyn Inc. [See Deal], Aton Pharma Inc. [See Deal], Egea Biosciences Inc.
The Better Exit for Private Biotechs: M&A
Does the recent flurry of acquisitions of private biotech companies by pharma companies represent a new and continuing trend? Yes--and a real change in thinking at Big Pharma and among VCs.
More from Strategy
More from Business
• By
While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.
• By
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
• By
Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.